The Global Health Body Raises Warning Over Severe Lack of Obesity Injections

Under a tenth of patients that would benefit from obesity jabs such as Wegovy have access to them, states the World Health Organization as it issues its inaugural advice on the therapies.

Given over a billion people worldwide now classified as obese, it is calling for increased and just availability to these injectable treatments.

Based on projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.

"Our latest guidance affirms that obesity is a chronic disease that can be managed with holistic and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are significant obstacles to broad availability to the injections that can assist patients in reducing considerable weight, says the agency.

Weight-Loss Drug Scarcity

Despite the present best projected scenario, the manufacturing of these medications would only suffice for around 100 million people – under 10% of the global need, according to the health organization.

The advice urges governments and firms to increase availability, by approaches like voluntary licensing.

A patent on semaglutide – the main component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.

The Way Obesity Drugs Operate

These medications imitate a natural hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so users eat less.

People usually begin shedding pounds after several weeks of commencing the weekly injections.

Evidence suggests users may see weight return a year later of stopping the treatment, as their normal appetite return.

Being overweight or obese elevates your likelihood for contracting health problems, like diabetes, heart disease, stroke, and specific cancers.

Obesity concerns individuals in every country and was linked to millions of fatalities worldwide in 2024, according to the health agency.